{
    "info": {
        "nct_id": "NCT06146920",
        "official_title": "Pilot Study Evaluation the Use of Serial Plasma Next-generation Sequencing (NGS) as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation",
        "inclusion_criteria": "* Adult patients age > 18) with unresectable, metastatic melanoma (cutaneous, acral, mucosal) or NSCLC who have evidence of disease control after at least 12 months of ICI based therapy (pembrolizumab, nivolumab, nivolumab-relatimab, ipilimumab/nivolumab, atezolizumab, ipilimumab, durvalumab, cemiplimab) with or without chemotherapy in the case of NSCLC. Any line of therapy is permitted with the exception of adjuvant therapy\n* Participants must be actively receiving standard of care ICI-based therapy (ICI monotherapy or in combination)\n* At time of enrollment patients must have received at least 12months (+/- 4 weeks) from the start of anti-PD-1 therapy and have not experienced a toxicity that prevented them from continuing therapy.\n* Participants must have evidence of disease control (stable disease, partial response, or complete response) that is maintained on restaging CT scans or PET CT scans obtained at 12 months (+/- 4 weeks) from the start of initial ICI therapy\n* Prior radiation to any site is allowed\n* Available tumor tissue (archival) for baseline tissue testing with FoundationOne CDx or previous FoundationOne CDx testing results (within 2 years and prior test results must be after June 30, 2021)\n* Life expectancy of greater than 3 months\n* Participants with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participants with clinical or radiographic evidence of progressive disease in the 3 months prior to consideration of screening and enrollment\n* Participants who are receiving an investigational agent (s)\n* Participants who have had ICI discontinued due an immune-related adverse event.\n* Patients with a history of an irAE but resumed ICI therapy and are receiving ICI at the time of screening are eligible to enroll.\n* Participants on > 10mg of oral prednisone or its equivalent for treatment of ongoing immune-related toxicity.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia, endocrine toxicity requiring chronic supplementation\n* Participants with a concurrent, active malignancy\n* Participants in whom F1CDx generation fails\n* Participants without available tumor tissue for F1CDx test result or prior F1CDx",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants must have evidence of disease control (stable disease, partial response, or complete response) that is maintained on restaging CT scans or PET CT scans obtained at 12 months (+/- 4 weeks) from the start of initial ICI therapy",
            "criterions": [
                {
                    "exact_snippets": "evidence of disease control (stable disease, partial response, or complete response)",
                    "criterion": "disease control status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "stable disease",
                                "partial response",
                                "complete response"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "maintained on restaging CT scans or PET CT scans obtained at 12 months (+/- 4 weeks) from the start of initial ICI therapy",
                    "criterion": "disease control status maintenance at 12 months",
                    "requirements": [
                        {
                            "requirement_type": "maintenance_duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 11.08,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12.92,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At time of enrollment patients must have received at least 12months (+/- 4 weeks) from the start of anti-PD-1 therapy and have not experienced a toxicity that prevented them from continuing therapy.",
            "criterions": [
                {
                    "exact_snippets": "patients must have received at least 12months (+/- 4 weeks) from the start of anti-PD-1 therapy",
                    "criterion": "duration of anti-PD-1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 11,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 13,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have not experienced a toxicity that prevented them from continuing therapy",
                    "criterion": "toxicity from anti-PD-1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "toxicity preventing continuation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of greater than 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of greater than 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior radiation to any site is allowed",
            "criterions": [
                {
                    "exact_snippets": "Prior radiation to any site is allowed",
                    "criterion": "prior radiation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment are eligible for this trial.",
            "criterions": [
                {
                    "exact_snippets": "Participants with a prior malignancy",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment",
                    "criterion": "potential for prior malignancy to interfere with safety or efficacy assessment",
                    "requirements": [
                        {
                            "requirement_type": "interference with safety or efficacy assessment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and the willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be actively receiving standard of care ICI-based therapy (ICI monotherapy or in combination)",
            "criterions": [
                {
                    "exact_snippets": "Participants must be actively receiving standard of care ICI-based therapy (ICI monotherapy or in combination)",
                    "criterion": "ICI-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "ICI monotherapy",
                                "ICI in combination"
                            ]
                        },
                        {
                            "requirement_type": "standard of care",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "active",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Available tumor tissue (archival) for baseline tissue testing with FoundationOne CDx or previous FoundationOne CDx testing results (within 2 years and prior test results must be after June 30, 2021)",
            "criterions": [
                {
                    "exact_snippets": "Available tumor tissue (archival) for baseline tissue testing",
                    "criterion": "tumor tissue (archival)",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous FoundationOne CDx testing results (within 2 years and prior test results must be after June 30, 2021)",
                    "criterion": "FoundationOne CDx testing results",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "date_of_test",
                            "expected_value": {
                                "operator": ">",
                                "value": 2021.5,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adult patients age > 18) with unresectable, metastatic melanoma (cutaneous, acral, mucosal) or NSCLC who have evidence of disease control after at least 12 months of ICI based therapy (pembrolizumab, nivolumab, nivolumab-relatimab, ipilimumab/nivolumab, atezolizumab, ipilimumab, durvalumab, cemiplimab) with or without chemotherapy in the case of NSCLC. Any line of therapy is permitted with the exception of adjuvant therapy",
            "criterions": [
                {
                    "exact_snippets": "Adult patients age > 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable, metastatic melanoma (cutaneous, acral, mucosal) or NSCLC",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "unresectable metastatic melanoma (cutaneous, acral, mucosal)",
                                "NSCLC"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of disease control after at least 12 months of ICI based therapy",
                    "criterion": "disease control after ICI therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "evidence of disease control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ICI based therapy (pembrolizumab, nivolumab, nivolumab-relatimab, ipilimumab/nivolumab, atezolizumab, ipilimumab, durvalumab, cemiplimab)",
                    "criterion": "prior ICI therapy",
                    "requirements": [
                        {
                            "requirement_type": "agent",
                            "expected_value": [
                                "pembrolizumab",
                                "nivolumab",
                                "nivolumab-relatimab",
                                "ipilimumab/nivolumab",
                                "atezolizumab",
                                "ipilimumab",
                                "durvalumab",
                                "cemiplimab"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without chemotherapy in the case of NSCLC",
                    "criterion": "chemotherapy for NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any line of therapy is permitted with the exception of adjuvant therapy",
                    "criterion": "line of therapy",
                    "requirements": [
                        {
                            "requirement_type": "adjuvant therapy exclusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participants without available tumor tissue for F1CDx test result or prior F1CDx",
            "criterions": [
                {
                    "exact_snippets": "Participants without available tumor tissue for F1CDx test result",
                    "criterion": "tumor tissue for F1CDx test result",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior F1CDx",
                    "criterion": "prior F1CDx",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who are receiving an investigational agent (s)",
            "criterions": [
                {
                    "exact_snippets": "Participants who are receiving an investigational agent (s)",
                    "criterion": "receipt of investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have had ICI discontinued due an immune-related adverse event.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have had ICI discontinued due an immune-related adverse event",
                    "criterion": "ICI (immune checkpoint inhibitor) treatment",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_due_to_immune-related_adverse_event",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants on > 10mg of oral prednisone or its equivalent for treatment of ongoing immune-related toxicity.",
            "criterions": [
                {
                    "exact_snippets": "> 10mg of oral prednisone or its equivalent for treatment of ongoing immune-related toxicity",
                    "criterion": "oral prednisone or its equivalent dosage",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "treatment of ongoing immune-related toxicity"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia, endocrine toxicity requiring chronic supplementation",
            "criterions": [
                {
                    "exact_snippets": "not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1)",
                    "criterion": "recovery from adverse events due to prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "residual_toxicity_grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia, endocrine toxicity requiring chronic supplementation",
                    "criterion": "residual toxicities (alopecia, endocrine toxicity requiring chronic supplementation)",
                    "requirements": [
                        {
                            "requirement_type": "allowable_residual_toxicity",
                            "expected_value": [
                                "alopecia",
                                "endocrine toxicity requiring chronic supplementation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of an irAE but resumed ICI therapy and are receiving ICI at the time of screening are eligible to enroll.",
            "criterions": [
                {
                    "exact_snippets": "history of an irAE",
                    "criterion": "history of immune-related adverse event (irAE)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "resumed ICI therapy",
                    "criterion": "resumption of immune checkpoint inhibitor (ICI) therapy",
                    "requirements": [
                        {
                            "requirement_type": "resumption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving ICI at the time of screening",
                    "criterion": "receiving immune checkpoint inhibitor (ICI) therapy at screening",
                    "requirements": [
                        {
                            "requirement_type": "current treatment status",
                            "expected_value": "receiving ICI at time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants in whom F1CDx generation fails",
            "criterions": [
                {
                    "exact_snippets": "Participants in whom F1CDx generation fails",
                    "criterion": "F1CDx generation",
                    "requirements": [
                        {
                            "requirement_type": "success",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with clinical or radiographic evidence of progressive disease in the 3 months prior to consideration of screening and enrollment",
            "criterions": [
                {
                    "exact_snippets": "clinical or radiographic evidence of progressive disease in the 3 months prior to consideration of screening and enrollment",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "evidence type",
                            "expected_value": [
                                "clinical",
                                "radiographic"
                            ]
                        },
                        {
                            "requirement_type": "progression timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a concurrent, active malignancy",
            "criterions": [
                {
                    "exact_snippets": "concurrent, active malignancy",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "concurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}